Search results for Eli Lilly
Industry
Jim Cramer picks 5 promising investment themes for second half of 2026
Five trends seen during the latest earnings season could determine investment opportunities for the rest of 2026, CNBC reported on Aug. 6. Jim Cramer (짐 크레이머) highlighted resilient consumers, AI infrastructure, cybersecurity, mergers and acquisitions and healthcare. He said investors should focus on broad market themes rather than individual companies. Cramer cited Capital One, American Express, Ralph Lauren and Williams Sonoma, and also named Lam Research, KLA and Applied Materials, as well as CrowdStrike, Palo Alto Networks, Goldman Sachs, Morgan Stanley, Eli Lilly and Johnson & Johnson.
AI & Enterprise
Jim Cramer says these 5 non-tech stocks could rise if AI cools
CNBC host Jim Cramer warned that heavy positioning in technology stocks tied to the AI boom carries risks and urged investors to diversify. He said some signs of fatigue are emerging within tech even as AI and data centre names rebound. Cramer highlighted JPMorgan Chase, Johnson & Johnson, Kimberly-Clark, McDonald\'s, Yum Brands and Kraft Heinz as alternatives, citing relatively weak performance in finance, healthcare and staples. He also pointed to funding pressures from AI infrastructure spending and possible share issuance.
Industry
Lily\'s new obesity drug retatrutide eyes beyond GLP-1 limits tagged with fatigue
Eli Lilly\'s next-generation obesity treatment retatrutide may reduce fatigue, a side effect often associated with GLP-1 drugs, by regulating energy metabolism as well as suppressing appetite. Retatrutide is designed as a triple agonist that stimulates GLP-1, GIP and glucagon receptors. This mechanism could promote fat and glycogen breakdown while boosting insulin and limiting blood sugar spikes. Gigazine said clinical data are not yet sufficient to confirm the effect.